Karuna Therapeutics Inc (DELISTED) (KRTX:DL)
329.83
0.00 (0.00%)
USD |
NASDAQ |
Mar 18, 16:00
Karuna Therapeutics Cash from Financing (Quarterly): 19.87M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 19.87M |
| September 30, 2023 | 2.659M |
| June 30, 2023 | 18.40M |
| March 31, 2023 | 442.45M |
| December 31, 2022 | 5.385M |
| September 30, 2022 | 844.19M |
| June 30, 2022 | 4.948M |
| March 31, 2022 | 1.257M |
| December 31, 2021 | 3.75M |
| September 30, 2021 | 0.749M |
| June 30, 2021 | 2.253M |
| March 31, 2021 | 270.82M |
| Date | Value |
|---|---|
| December 31, 2020 | 1.545M |
| September 30, 2020 | 0.525M |
| June 30, 2020 | 1.072M |
| March 31, 2020 | 0.517M |
| December 31, 2019 | 234.22M |
| September 30, 2019 | 94.24M |
| June 30, 2019 | 0.314M |
| March 31, 2019 | 76.50M |
| December 31, 2018 | 2.70M |
| September 30, 2018 | 17.88M |
| June 30, 2018 | 4.00M |
| March 31, 2018 | 3.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.314M
Minimum
Jun 2019
844.19M
Maximum
Sep 2022
102.59M
Average
3.75M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 14.64B |
| RayzeBio inc (DELISTED) | 314.84M |
| Icosavax Inc (DELISTED) | -0.208M |
| Madrigal Pharmaceuticals Inc | 479.92M |
| Theseus Pharmaceuticals Inc (DELISTED) | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -111.06M |
| Cash from Investing (Quarterly) | 92.44M |
| Free Cash Flow | -388.74M |
| Free Cash Flow Per Share (Quarterly) | -2.96 |
| Free Cash Flow Yield | -3.19% |